Vitalhub Corp. (TSE:VHI - Get Free Report) has been assigned an average rating of "Buy" from the five ratings firms that are covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is C$12.08.
A number of research firms have issued reports on VHI. Canaccord Genuity Group increased their price target on Vitalhub from C$12.00 to C$12.50 and gave the company a "buy" rating in a research report on Thursday, January 16th. Scotiabank set a C$14.00 price target on Vitalhub and gave the stock an "outperform" rating in a report on Thursday, January 30th. TD Securities increased their price objective on Vitalhub from C$13.00 to C$14.00 and gave the company a "buy" rating in a report on Monday. Finally, Raymond James set a C$13.50 price target on Vitalhub and gave the company an "outperform" rating in a report on Thursday.
View Our Latest Report on VHI
Vitalhub Stock Performance
Shares of TSE:VHI traded down C$0.09 during trading on Thursday, hitting C$10.15. The company's stock had a trading volume of 154,101 shares, compared to its average volume of 146,944. The company has a market capitalization of C$549.04 million, a PE ratio of 165.09, a P/E/G ratio of 1.18 and a beta of 1.26. Vitalhub has a fifty-two week low of C$5.80 and a fifty-two week high of C$12.09. The business has a 50 day moving average price of C$10.48 and a two-hundred day moving average price of C$10.35.
About Vitalhub
(
Get Free ReportVitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.
Recommended Stories
Before you consider Vitalhub, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vitalhub wasn't on the list.
While Vitalhub currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
